DELTICOM-AG
23.2.2017 16:04:44 CET | Business Wire | Press release
Reinforcement in the B2B area at Europe’s largest online tyre wholesaler, Delticom: Since January 2017, Nathalie Kronenberg has been in charge of Key Account Management B2B of the listed company with headquarters in Hanover. From there, the 38-year-old will lead the strategic development of the company’s B2B key accounts worldwide. In addition to building the European trade, Kronenberg’s tasks also include expanding the business to America and the Asia/Pacific region, as well as further promoting the digitisation of the company’s bulk business. Delticom already operates online shops for wholesale customers in many European countries and further afield, for example Yourtyres.co.uk and Fleettyres24.co.uk in Great Britain.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170223006040/en/
“Welcoming Nathalie on board means gaining an expert with an excellent network who will provide us with valuable support, especially in the further internationalisation and digitisation of our bulk business”, explains Andreas Faulstich, Head of B2B at Delticom. “I am in no doubt that Nathalie’s professional expertise and human qualities will enable her to strengthen our B2B trade worldwide, and that above all she will be a helpful partner to our key customers.” Ms Kronenberg, a qualified economist, has been involved in the wholesale tyre industry since 2004, and brings a wealth of experience from the sector, including key positions in purchasing and international wholesale, especially in Asia.
“I’m looking forward to the upcoming challenges. Together with Delticom’s B2B team, I want to build on the company’s existing strengths, as well as focusing on the strategic development of our key wholesale accounts. Delticom has already enjoyed much success with its B2B services. The next step is to take this partnership-based trading model and continue to optimise and expand it, for example through new delivery methods”, says Ms Kronenberg. According to Kronenberg, all parties will profit from the planned expansion of the key account trade: “My aim is to develop a holistic approach that allows our key customers to become partners in the bulk business, retail, and e-commerce sectors.”
About Delticom:
Delticom is Europe's leading online retailer of tyres and automotive accessories. Founded in 1999, the Hannover-based company operates more than 300 online shops and websites in 41 countries, including ReifenDirekt in Germany, Austria and Switzerland. The Delticom Group also owns the shops of Tirendo. The broad product range for private and corporate customers comprises more than 100 brands and more than 25,000 models of tyres for cars, motorbikes, trucks, commercial vehicles and buses, as well as complete wheels.
Customers enjoy all the benefits of modern e-commerce: easy ordering at home, a high ability to supply, and, not least, attractive prices. Goods are delivered within two working days on average, either to a customer's home address or an alternatively designated address. Customers can also have their tyres delivered to one of more than 44,000 service partners worldwide (with 2,100 in Great Britain alone), which provide professional and cost-effective tyre fitting services for the Group's customers. More than 300,000 new vehicle parts, including motor oils, automotive spare parts and automotive accessories round out the product range.
In the efood area, Delticom AG is a leader in automated logistics processes and offers a comprehensive range of foodstuffs: a total of 17,000 articles are available in the German gourmet online supermarket Gourmondo.de alone.
On the Internet at: www.delti.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170223006040/en/
Contact:
insignis Agentur für
Kommunikation GmbH (GPRA)
Henning Jahns
Tel.:
+49-511-132214-14
Fax: +49-511-132214-99
delticom@insignis.de
or
Delticom
AG
Anne Lena Peters
Tel.: +49-511-93634-8909
Fax:
+49-511-93634-8301
anne.lena.peters@delti.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
